Πλοήγηση ανά Συγγραφέα "Hatzidaki, E."

Bortezomib Downregulates MGMT Expression in T98G Glioblastoma Cells

Vlachostergios, P. J.; Hatzidaki, E.; Stathakis, N. E.; Koukoulis, G. K.; Papandreou, C. N. (2013)

The efficacy of treatment for glioblastoma multiforme is currently limited by the development of resistance, particularly, but not exclusively, due to the expression of the DNA repair enzyme O6-methylguanine methyltransferase ...

Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner

Vlachostergios, P. J.; Hatzidaki, E.; Befani, C. D.; Liakos, P.; Papandreou, C. N. (2013)

Development of drug resistance after standard chemotherapy for glioblastoma multiforme (GBM) with temozolomide (TMZ) is associated with poor prognosis of GBM patients and is at least partially mediated by a direct DNA ...

Bortezomib represses HIF-1 alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

Befani, C. D.; Vlachostergios, P. J.; Hatzidaki, E.; Patrikidou, A.; Bonanou, S.; Simos, G.; Papandreou, C. N.; Liakos, P. (2012)

Bortezomib represents the first proteasome inhibitor (PI) with demonstrated antitumor activity in the clinical setting, particularly for treatment of hematological malignancies. At the preclinical level, its action is shown ...

Bortezomib represses HIF-1 alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells (vol 90, pg 45, 2012)

Befani, C. D.; Vlachostergios, P. J.; Hatzidaki, E.; Patrikidou, A.; Bonanou, S.; Simos, G.; Papandreou, C. N.; Liakos, P. (2013)

Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells

Tsapakidis, K.; Vlachostergios, P. J.; Voutsadakis, I. A.; Befani, C. D.; Patrikidou, A.; Hatzidaki, E.; Daliani, D. D.; Moutzouris, G.; Liakos, P.; Papandreou, C. N. (2012)

Objectives: Neuropeptides are important signal initiators in advanced prostate cancer, partially acting through activation of nuclear factor kappa B. Central to nuclear factor kappa B regulation is the ubiquitin-proteasome ...

Effect of ET-1, FGF-2, and HGF on intracellular steroidogenesis in prostate cancer cells

Vasileiou, C.; Hatzidaki, E.; Karkabounas, A.; Maragkouli, E.; Vaiou, M.; Dimas, K.; Liakos, P.; Lekka, M.; Papandreou, C. (2013)

Evidence of Association Between Methylenetetrahydrofolate Reductase Gene and Susceptibility to Breast Cancer: A Candidate-Gene Association Study in a South-Eastern European Population

Papandreou, C. N.; Doxani, C.; Zdoukopoulos, N.; Vlachostergios, P. J.; Hatzidaki, E.; Bakalos, G.; Ziogas, D. C.; Koufakis, T.; Zintzaras, E. (2012)

The methylenetetrahydrofolate reductase (MTHFR) gene has been proposed as a candidate gene for breast cancer (BC). However, the specific role of MTHFR polymorphisms and haplotypes has not been fully clarified and replicated. ...

MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NF kappa B and mutant p53

Vlachostergios, P. J.; Hatzidaki, E.; Papandreou, C. N. (2013)

The DNA repair enzyme O6-methylguanine methyltransferase (MGMT) is a major determinant of glioma resistance to alkylating agents. Several strategies have been used to induce sensitization to alkylator-based treatments, ...

Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer

Vlachostergios, P. J.; Gioulbasanis, I.; Ghosh, S.; Tsatsanis, C.; Papatsibas, G.; Xyrafas, A.; Hatzidaki, E.; Vasiliou, C.; Kamposioras, K.; Agelaki, S.; Margioris, A. N.; Nasi, D.; Georgoulias, V.; Papandreou, C. N. (2013)

Cancer patients usually develop malnutrition which may alter their innate immune system integrity. The aim of this study was to investigate the clinical relevance of chemokine response after lipopolysaccharide (LPS)-stimulation ...